The CEO Roundtable on Cancer has accredited AREVA Med with the CEO Cancer Gold StandardTM recognizing the company’s efforts to reduce the risk of cancer for its employees and covered family members.
This nonprofit organization of CEOs, founded by former President George H.W. Bush, created the Gold Standard in collaboration with the National Cancer Institute (NCI), many of its designated cancer centers and other leading health organizations. The Gold Standard requires employers to evaluate their health benefits and corporate culture and to take extensive, concrete actions in five key areas of health and wellness to reduce the risk of cancer in the workplace.
“Our Gold Standard certification acknowledges the personal leadership of Chief Executive Officer Patrick Bourdet and recognizes that AREVA Med’s efforts to improve health begin with the company’s own employees and their family members,” said Christopher A. Viehbacher, Chairman of the CEO Roundtable on Cancer.
To earn Gold Standard accreditation, an employer must establish programs to reduce cancer risk by prohibiting tobacco use and supporting tobacco cessation efforts, further encouraging prevention by promoting physical activity, healthy nutrition and weight management; detecting cancer at its earliest stages; and providing access to quality care, including participation in clinical trials. Today, over four and a half million employees and family members are benefiting from the vision and leadership of 175 employers who have chosen to become Gold Standard accredited.
“In line with its core activities to develop innovative cancer therapies, AREVA Med is honored to receive this prestigious accreditation and to join an impressive list of organizations committed to supporting cancer prevention, early detection, and treatment for their employees,” said Patrick Bourdet, CEO of AREVA Med. “In addition to our clinical research, our company’s wellness policies are a testament to our dedication to the fight against cancer.”
In addition to NCI and the Centers for Disease Control and Prevention, 16 NCI-designated cancer centers and more than 60 other hospitals have earned Gold Standard accreditation. CEOs from many industries are keenly aware of the life-improving impact they can have on health and controlling healthcare costs when they address cancer and other chronic diseases. Gold Standard employers include: Avis Budget Group, Harvard School of Public Health, Lowe’s, Aetna, State Farm, Hogan Lovells, Dell, Johnson & Johnson, Novartis, SAS and many Blue Cross affiliates.
About AREVA Med
AREVA Med is an AREVA subsidiary created in 2009 to develop innovative therapies to fight cancer. AREVA Med has developed new processes for producing high-purity lead-212 (²¹²Pb), a rare radioactive isotope. 212Pb is currently at the heart of promising research projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells without damaging nearby healthy cells. In 2011, AREVA Med acquired Macrocyclics, the global leader in high performance chelating agent technology. AREVA Med is also associated with world-class scientific partners, such as the National Cancer Institute (NCI), the University of Alabama at Birmingham (UAB), and the French National Institute of Health and Medical Research (Inserm). In 2012, AREVA Med and Roche entered a strategic collaboration to create novel advanced alpha radioimmunotherapy treatments to target and kill certain very aggressive types of cancer cells. For more information: www.arevamed.com. Follow @AREVAmed on Twitter.